Business
New to The Street TV Announces its Line-ups Airing on the Fox Business Network, Episode #308, Tonight Monday, February 21, 2022, 10:30 PM PT and Episode #309, Tomorrow Night, Tuesday, February 22, 2022, 10:30 PM PT
New to The Street TV Announces its Line-ups Airing on the Fox Business Network, Episode #308, Tonight Monday, February 21, 2022, 10:30 PM PT and Episode #309, Tomorrow Night, Tuesday, February 22, 2022, 10:30 PM PT.
About this update from Sibannac, Inc.
[{"type":"text","content":"\n NEW YORK, Feb. 21, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street TV, a nationally syndicated business show, announces its televised line-ups tonight, Monday, February 21, 2022, at 10:30 PM PT and Tuesday night, February 22, 2022, at 10:30 PM PT on the Fox Business Network. New to The Street’s 308th TV show, airs tonight, Monday, February 21, 2022, 10:30 PM PT, on the Fox Business Network, features the following five (5) Companies and their businesses representatives: 1). Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) interview, Dr. Seth Lederman, MD, CEO. 2). GlobeX Data, Ltd.’s (OTCQB: SWISF) (CSE: SWIS) (FRA: GDT) interview, Mr. Alain Ghiai, CEO. 3). Sibannac, Inc.’s (OTCPINK: SNNC) interview, Mr. David Mersky, CEO. 4). Cryptocurrency – Sportemon Go’s (CRYPTO: SGOX) ($SGOX) interview, Mr. Ricky Jackson, CEO. 5). GTX Corp’s (OTCPINK: GTXO) interview, Mr. Patrick Bertagna, CEO. New to The Street TV again, tonight, Monday, February 21, 2022, airs the CEO at Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP), Dr. Seth Lederman, MD’s interview with TV Anchor Jane King. Dr. Lederman gives the New to The Street TV audience an update about Tonix Pharmaceuticals, Inc.’s Covid-19 vaccine, antiviral pharmaceutical, and “Long” Covid-19 novel treatments and products. Currently, in the market, there are three (3) types of treatments in the fight against Covid-19: mRNA vaccines, antiviral therapies, and monoclonal antibodies. Seth gives a comparison and talks about the limitations of each available Covid-19 treatment. TNXP’s live vaccine, TNX-1800, in development, offers long-term protection beyond the currently used mRNA vaccines. Another in development therapy, the Company’s TNX-3500, an oral antiviral pharmaceutical, clinically shows about 65 times more potent than remdesivir in inhibiting Covid. Test combining TNX-3500 and remdesivir shows a robust protective solution. TNX-3500 is an investigational new drug not yet approved for use. Seth talks about the Company’s upcoming clinical trials on its treatment for “Long Covid.” With its new 40,000+ sq. ft. location in Fedrick, Maryland, a known biotech /biodefense sector area in the US, the facility and its personnel allow ongoing clinical trials and scientific development program...